Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation

Nature Communications

Volumn 5, Issue , 2014, Pages

  Sashida, Goro ^a,b   Harada, Hironori ^c,h   Matsui, Hirotaka ^c   Oshima, Motohiko ^a,b   Yui, Makiko ^a,b   Harada, Yuka ^c,h   Tanaka, Satomi ^a,d   Mochizuki Kashio, Makiko ^a,b   Wang, Changshan ^a,b   Saraya, Atsunori ^a,b   Muto, Tomoya ^a,d   Hayashi, Yoshihiro ^e   Suzuki, Kotaro ^a   Nakajima, Hiroshi ^a   Inaba, Toshiya ^c   Koseki, Haruhiko ^b,f   Huang, Gang ^e   Kitamura, Toshio ^g   Iwama, Atsushi ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY HOSPITAL   (Japan)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f RIKEN Center for Integrative Medical Sciences   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR HOXA9; EZH2 PROTEIN, HUMAN; EZH2 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; RUNX1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR RUNX1;

BIOCHEMISTRY; BLOOD SYSTEM DISORDER; CANCER; FUNCTIONAL ROLE; GENE EXPRESSION; MUTATION; PATHOLOGY; RODENT; TRANSFORMATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BONE MARROW; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE TARGETING; HEMATOPOIETIC STEM CELL; HEMOGLOBIN BLOOD LEVEL; LEUKEMIA; MEAN CORPUSCULAR VOLUME; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NULL CELL; PROTEIN DEPLETION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL TRANSFORMATION; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY;

ANIMALS; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELODYSPLASTIC SYNDROMES; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84903178102     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5177     Document Type: Article

References (54)

1. Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496-2506 (2011).
2. Shih, A. H., Abdel-Wahab, O., Patel, J. P. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599-612 (2012).
3. Chung, Y. R., Schatoff, E. & Abdel-Wahab, O. Epigenetic alterations in hematopoietic malignancies. Int. J. Hematol. 96, 413-427 (2012).
4. Sashida, G. & Iwama, A. Epigenetic regulation of hematopoiesis. Int. J. Hematol. 96, 405-412 (2012).
5. Sauvageau, M. & Sauvageau, G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299-313 (2010).
6. Wang, H. et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873-878 (2004). (Pubitemid 39434086)
7. Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043 (2002). (Pubitemid 35247314)
8. Boyer, L. a. et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349-353 (2006).
9. Francis, N. J., Kingston, R. E. & Woodcock, C. L. Chromatin compaction by a polycomb group protein complex. Science 306, 1574-1577 (2004). (Pubitemid 39564957)
10. Tavares, L. et al. RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 148, 664-678 (2012).
11. Simon, J. a. & Kingston, R. E. Occupying chromatin: polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol. Cell 49, 808-824 (2013).
12. Yu, M. et al. Direct recruitment of Polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol. Cell 45, 330-343 (2012).
13. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
14. Herrera-Merchan, A. et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat. Commun. 3, 623 (2012).
15. Tanaka, S. et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120, 1107-1117 (2012).
16. Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722-726 (2010).
17. Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665-667 (2010).
18. Bejar, R. et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30, 3376-3382 (2012).
19. Jerez, A. et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 119, 6109-6117 (2012).
20. Muto, T. et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J. Exp. Med. 210, 2627-2639 (2013).
21. Niimi, H. et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia. 20, 635-644 (2006).
22. Harada, H. et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103, 2316-2324 (2004). (Pubitemid 38326252)
23. Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616-3627 (2013).
24. Watanabe-Okochi, N. et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111, 4297-4308 (2008).
25. Sawada, K. et al. Proliferation and differentiation of myelodysplastic CD34 cells: phenotypic subpopulations of marrow CD34 cells. Blood 85, 194-202 (1995).
26. Passegué, E., Jamieson, C. H. M., Ailles, L. E. & Weissman, I. L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl Acad. Sci. USA 100 (suppl.), 11842-11849 (2003). (Pubitemid 37205893)
27. Walkley, C. R. et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129, 1097-1110 (2007). (Pubitemid 46908696)
28. Raaijmakers, M. H. G. P. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857 (2010).
29. Zhang, B. et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21, 577-592 (2012).
30. Schepers, K. et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285-299 (2013).
31. Su, I. et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121, 425-436 (2005). (Pubitemid 40692302)
32. Mochizuki-Kashio, M. et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood 118, 6553-6561 (2011).
33. Kogan, S. C. et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100, 238-245 (2002). (Pubitemid 35177453)
34. Nimer, S. D. MDS: a stem cell disorder-but what exactly is wrong with the primitive hematopoietic cells in this disease? Hematology. 2008, 43-51 (2008).
35. Raza, A. & Galili, N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat. Rev. Cancer 12, 849-859 (2012).
36. Abdel-Wahab, O. et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 210, 2641-2659 (2013).
37. Shen, X. et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491-502 (2008).
38. Chambers, S. M. et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell 1, 578-591 (2007). (Pubitemid 350056409)
39. Goyama, S. & Kurokawa, M. Evi-1 as a critical regulator of leukemic cells. Int. J. Hematol. 91, 753-757 (2010).
40. Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003). (Pubitemid 37448928)
41. Essers, M. a. G. et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458, 904-908 (2009).
42. King, K. Y. & Goodell, M. a. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685-692 (2011).
43. Chen, C., Liu, Y., Liu, Y. & Zheng, P. Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice. J. Clin. Invest. 120, 4091-4101 (2010).
44. Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006). (Pubitemid 44258912)
45. Takeda, A., Goolsby, C. & Yaseen, N. R. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34 hematopoietic cells. Cancer Res. 66, 6628-6637 (2006). (Pubitemid 44085619)
46. Lawrence, H. J. et al. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 106, 3988-3994 (2005). (Pubitemid 41739043)
47. Harada, Y. et al. RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood 121, 3434-3446 (2013).
48. Thorsteinsdottir, U. et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99, 121-129 (2002).
49. Starczynowski, D. T. et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat. Med. 16, 49-58 (2010).
50. Chiba, T. et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 133, 937-950 (2007). (Pubitemid 47374130)
51. Konuma, T. et al. Forced expression of the histone demethylase Fbxl10 maintains self-renewing hematopoietic stem cells. Exp. Hematol. 39, 697-709 (2011).
52. Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics. 27, 1571-1572 (2011).
53. Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
54. Dasu, M. R. K., Hawkins, H. K., Barrow, R. E., Xue, H. & Herndon, D. N. Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. J. Pathol. 202, 476-485 (2004). (Pubitemid 38456166)